Lennox International (NYSE: LII) and AmpliPhi Biosciences (NASDAQ:TGEN) are both construction companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
This is a breakdown of current ratings and price targets for Lennox International and AmpliPhi Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Lennox International and AmpliPhi Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Lennox International and AmpliPhi Biosciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Lennox International||$3.84 billion||2.03||$305.70 million||$7.92||23.90|
|AmpliPhi Biosciences||$33.20 million||2.33||$40,000.00||N/A||N/A|
Lennox International has higher revenue and earnings than AmpliPhi Biosciences.
Lennox International pays an annual dividend of $2.04 per share and has a dividend yield of 1.1%. AmpliPhi Biosciences does not pay a dividend. Lennox International pays out 25.8% of its earnings in the form of a dividend. Lennox International has raised its dividend for 6 consecutive years.
Risk & Volatility
Lennox International has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, AmpliPhi Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.
Insider and Institutional Ownership
70.0% of Lennox International shares are owned by institutional investors. Comparatively, 10.1% of AmpliPhi Biosciences shares are owned by institutional investors. 3.9% of Lennox International shares are owned by company insiders. Comparatively, 19.5% of AmpliPhi Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Lennox International beats AmpliPhi Biosciences on 10 of the 15 factors compared between the two stocks.
About Lennox International
Lennox International Inc., together with its subsidiaries, provides climate control solutions in the United States, Canada, and internationally. It designs, manufactures, and markets a range of products for the heating, ventilation, air conditioning, and refrigeration markets. The company operates in three segments: Residential Heating & Cooling, Commercial Heating & Cooling, and Refrigeration. The Residential Heating & Cooling segment provides furnaces, air conditioners, heat pumps, packaged heating and cooling systems, indoor air quality equipment, comfort control products, and replacement parts and supplies for residential replacement and new construction markets. The Commercial Heating & Cooling segment offers rooftop units, split system/air handler combinations, small package units, chillers, and fan coils for commercial buildings, shopping malls, other retail and entertainment buildings, institutional, and other field-engineered applications; and variable refrigerant flow commercial products. This segment also engages in the installation and service of commercial heating and cooling equipment. The Refrigeration segment offers condensing units, unit coolers, fluid coolers, air cooled condensers, air handlers, display cases, and refrigeration rack systems that helps in preserving food and other perishables in supermarkets, convenience stores, restaurants, warehouses, and distribution centers, as well as for data centers, machine tooling, and other cooling applications; and compressor racks and industrial process chillers. The company sells its products and services through direct sales, distributors, and company-owned parts and supplies stores. Lennox International Inc. was founded in 1895 and is headquartered in Richardson, Texas.
About AmpliPhi Biosciences
Tecogen Inc. designs, manufactures, and sells industrial and commercial cogeneration systems that produce combinations of electricity, hot water, and air conditioning in the United States and internationally. It operates through two segments, Products and Services and Energy Production. The company offers InVerde e+, a cogeneration product that provides electricity and hot water; TECOGEN cogeneration systems for producing hot water; TECOCHILL air-conditioning and refrigeration chillers; and water heaters under the Ilios brand name, as well as emissions control technology under Ultera brand name. It also provides long-term maintenance contracts, parts sales, and turnkey installation services through a network of nine field service centers in California, the Midwest, and the Northeast. In addition, the company installs, owns, operates, and maintains distributed generation of electricity systems and other complementary systems. It serves hospitals and nursing homes, colleges and universities, health clubs and spas, hotels and motels, office and retail buildings, food and beverage processors, multi-unit residential buildings, laundries, ice rinks, swimming pools, factories, municipal buildings, military installations, and indoor growing facilities. The company was incorporated in 2000 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Lennox International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lennox International and related companies with MarketBeat.com's FREE daily email newsletter.